AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03339661
Drug: Group 1_No proph treatment
RxNorm normalized name: no 'zit' sherlock spot treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, expansion of γδ T cell at the end curative treatment was detected, so secondary prophylaxis will not be started.
Trial: NCT01663233
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
Trial: NCT01663233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to LCZ696
Trial: NCT02321098
Drug: Loceryl NL 12 weeks
RxNorm normalized name: glyceryl 1,2-dioleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loceryl NL once/week for 12 weeks
Trial: NCT02222207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops
Trial: NCT03343587
Drug: LY3375880 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered IV
Trial: NCT03343587
Drug: LY3375880 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered SC
Trial: NCT03343587
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered IV
Trial: NCT03343587
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered SC
Trial: NCT00622648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
Trial: NCT02187471
Drug: DS-5565
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-5565 15 mg QD or BID; tablet for oral use
Trial: NCT02187471
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet for oral use, matching DS-5565 tablet
Trial: NCT00522431
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% gel
Trial: NCT00004231
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004231
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004231
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004231
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03388853
Drug: Acetylcysteine/Doxofylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
Trial: NCT03285594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Trial: NCT00665457
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00665457
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00665457
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00665457
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03285594
Drug: Oral Antidiabetes Drugs (OADs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OADs (including metformin) as prescribed by the investigator as per local labeling.
Trial: NCT04195321
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: infusion will be started after induction of spinal anesthesia
Trial: NCT02325219
Drug: CTNO 1959 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous injection of CNTO 1959 100 mg.
Trial: NCT02325219
Drug: Placebo 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
Trial: NCT02325219
Drug: Placebo 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
Trial: NCT01525004
Drug: High-Dose trivalent inactivated influenza vaccine
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
Trial: NCT01525004
Drug: Standard dose trivalent inactivated influenza vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
Trial: NCT00935168
Drug: 6% Hydroxy-ethyl starch (130/0.4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
Trial: NCT00878020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0mg, Single Dose, 1 day
Trial: NCT00878020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
Trial: NCT03551444
Drug: Administration of DAA-based treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~* HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~* During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~* Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~* SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~* Virological failures and early discontinuations of therapy due to adverse events will be also registered.
Trial: NCT01263171
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01263171
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01263171
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01652183
Drug: intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03165097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching ACT-709478 capsules
Trial: NCT03588923
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, oral, once daily for 3 days
Trial: NCT05220527
Drug: vitagen plus hyruan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitagen plus hyruan injections, one time per week, for 3 weeks
Trial: NCT02669017
Drug: ADCT-402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT02313155
Drug: Subcutaneous injection of TAK-850
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-850 0.5 mL, Subcutaneous injection
Trial: NCT02313155
Drug: Intramuscular injection of TAK-850
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-850 0.5 mL, Intramuscular injection
Trial: NCT03385564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT00932347
Drug: Camellia sinensis mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mouthrinsing, 2 times/day, for 28 days
Trial: NCT00932347
Drug: Placebo mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mouthrinsing, 2 times/day, for 28 days
Trial: NCT00466167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03199963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
Trial: NCT00836849
Drug: Zoloft® 100 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 100 mg, single-dose fed
Trial: NCT00223925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00868413
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Trial: NCT00404014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of placebo
Trial: NCT00691964
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ placebo injections for ABT-874 and etanercept
Trial: NCT00097760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
Trial: NCT01478035
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
Trial: NCT03778619
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
Trial: NCT00037180
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00037180
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04609852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion.
Trial: NCT02640417
Drug: B Vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with vitamins B1, B6, and B12
Trial: NCT00864435
Drug: Coreg® 12.5 mg Tablets , single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
Trial: NCT00663065
Drug: PAZ-417
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03393208
Drug: Test GIR
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Trial: NCT03393208
Drug: Reference GIR
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Trial: NCT01947920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Size-matching capsules containing an appropriate inactive excipient
Trial: NCT00418145
Drug: megadose oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1400 mg qd/5 days
Trial: NCT00418145
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg/qd/5 days
Trial: NCT00840411
Drug: Clarithromycin ER 500 mg tablets
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 500 mg
Trial: NCT00840411
Drug: BIAXIN® XL 500 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 500 mg
Trial: NCT00833937
Drug: AMBIEN® 10 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg
Trial: NCT03106038
Drug: Nerindocianine for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedure: routine minimally invasive pelvic surgery.
Trial: NCT00807794
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.012 mg/kg dose given twice between 60 to 72 hours apart
Trial: NCT00807794
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg/kg dose given twice between 60 to 72 hours apart
Trial: NCT02141711
Drug: TAK-438 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets
Trial: NCT00023374
Drug: REZ
RxNorm normalized name: Breze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rif+PZA+EMB given 2 or 3 times weekly for 6 months
Trial: NCT00807794
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 mg/kg dose given twice between 60 to 72 hours apart
Trial: NCT00807794
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
Trial: NCT03134352
Drug: ZL-3101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
Trial: NCT00835536
Drug: COPEGUS™ 200 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 200 mg, single-dose non-fasting
Trial: NCT03134352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
Trial: NCT02137954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03173547
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream does not contain an active drug and is applied topically.
Trial: NCT02599701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single placebo dose with the same physical characteristics of the active intervention.
Trial: NCT01951820
Drug: Benzocaine
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
Trial: NCT01788254
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
Trial: NCT01788254
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
Trial: NCT02749890
Drug: Oral anti-diabetic drugs
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: Oral
Trial: NCT02364089
Drug: Standardized medical treatment of hypertension by SAHR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~* step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~* step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~* step 4: Add-on of Indapamide LP 1.5 mg~* step 5: Add-on of Spironolactone 25 mg~* step 6: Add-on of Bisoprolol 10 mg~* step 7: Add-on of Prazosine LP 5mg/day.
Trial: NCT01445821
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An alkylating agent which causes prevention of cell division by forming adducts with DNA
Trial: NCT00531752
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
Trial: NCT00326352
Drug: Sedation with propofol and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00619073
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
Trial: NCT03311594
Drug: Low Alcohol
RxNorm normalized name: Low alcohol beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Alcohol Consumption
Trial: NCT00592215
Drug: Experimental (mifepristone and misoprostol)
RxNorm normalized name: naproxen and misoprostol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
Trial: NCT03311594
Drug: Placebo Alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Alcohol Consumption
Trial: NCT02559440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 puff in each nostril every evening
Trial: NCT02559440
Drug: Placebo + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 puff of placebo +1 puff of Placebo in each nostril every evening
Trial: NCT04540042
Drug: Placebo (Part 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V., multiple-dose (Day 1 and Day 22)
Trial: NCT04540042
Drug: Placebo (Part 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V., single-dose (Day 1)
Trial: NCT03776058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT03374176
Drug: Clindamycin 300 mg
RxNorm normalized name: clindamycin 300 MG
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects were instructed to take a capsule three times a day for 7 days
Trial: NCT01881464
Drug: Anti TNF Alfa.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
Trial: NCT01248975
Drug: FP/SAL 250/50mcg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/SAL 250/50mcg BID
Trial: NCT01248975
Drug: GSK2190915 200mg QD (AM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 200mg QD (AM)
Trial: NCT02821715
Drug: THN102 300/3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04081350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01248975
Drug: GSK2190915 100mg QD (AM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 100mg QD (AM)
Trial: NCT01248975
Drug: Placebo tablets (2) (AM)
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (2) (AM)
Trial: NCT01248975
Drug: Placebo capsule (PM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule (PM)
Trial: NCT02788747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of placebo administered once daily for 28 consecutive days
Trial: NCT01290380
Drug: ASA404, DMXAA, DXAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
Trial: NCT03456752
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 1.6ml intravenously prior to induction of anesthesia
Trial: NCT01223703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study
Trial: NCT02911701
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00784654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once per day (double-blind period)
Trial: NCT03458208
Drug: Glucophage®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition
Trial: NCT03458208
Drug: Glucophage®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition